Motor Neurone Disease Trial, Recruiting NCT06528964 Sponsor: Universidad Autonoma de San Luis Potosí Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06528964
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have a neurological condition:

  • You are 45 years of age or older
  • You are a man or a woman
  • You have been diagnosed with one of the following conditions: Alzheimer's disease, frontotemporal lobe dementia (a type of dementia), Parkinson's disease, atypical Parkinsonism (a Parkinson's-related condition), ALS (also known as Lou Gehrig's disease), or normal pressure hydrocephalus (a condition involving fluid buildup in the brain)
  • You are willing to take part in the study and sign a consent form

If you are a healthy volunteer (control participant):

  • You are 45 years of age or older
  • You are a man or a woman
  • You may be related to a patient in the study, but not by blood (for example, a patient's spouse)
  • You do not have any close blood relatives with a neurodegenerative disease
  • You have no signs or symptoms suggesting dementia
  • You are willing to take part in the study and sign a consent form

Who may not be able to join:

  • Anyone who has a personal history of stroke or other blood vessel-related brain conditions, psychiatric illness, dementia caused by a head injury, or dementia related to HIV
  • Patients whose diagnosis is uncertain or has not yet been officially confirmed
  • Anyone who has an active infection affecting the brain or nervous system
  • Anyone who has been diagnosed with a skin disease
  • Patients whose condition is considered to present in an unusual or "atypical" way (confirm with trial site)
  • Anyone who has a condition that affects their blood's ability to clot properly

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +52 444 834 2739

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universidad Autonoma de San Luis Potosí
Registry
ClinicalTrials.gov
Start date
20 December 2023
Est. completion
25 October 2026

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Aggregation pattern of a-synuclein, amyloid-b, p-TAU and TDP-43

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov